Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced

Objective Evaluation of the efficacy and safety of guselkumab, a human monoclonal antibody targeting the interleukin-23p19 subunit, in patients with psoriatic arthritis (PsA) through 1 year.Methods Adults who met ClASsification criteria for Psoriatic ARthritis, with active disease (≥3 swollen and ≥3...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Atul Deodhar, Shihong Sheng, Philip S Helliwell, Soumya D Chakravarty, Elizabeth C Hsia, Enrique R Soriano, Chetan S Karyekar, Wolf-Henning Boehncke, Prasheen Agarwal, Alexa P Kollmeier, Federico Zazzetti, Ramanand A Subramanian, Xie L Xu, Qing C Zuraw, Yusang Jiang, Bei Zhou, Yanli Zhuang, May Shawi
Formato: article
Lenguaje:EN
Publicado: BMJ Publishing Group 2021
Materias:
Medicine
R
Acceso en línea:https://doaj.org/article/ae559d22818b49b5b84a51d05b30ba53
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/ae559d22818b49b5b84a51d05b30ba53

Ejemplares similares